Study on Legal Responsibility of Drug Clinical Trials in America
SUN Yu-xin1, WEI Feng-fang1,2, YANG Yue1,2,*
1 College of Business Administration, Shenyang Pharmaceutical University, Liaoning Shenyang 110016, China;
2 International Food and Drug Policy and Law Center, Liaoning Shenyang 110016, China
SUN Yu-xin, WEI Feng-fang, YANG Yue. Study on Legal Responsibility of Drug Clinical Trials in America[J]. Chinese Journal of Pharmacovigilance, 2017, 14(7): 424-429.
[1] FDA. Warning Letters[EB/OL].(2017-01-02)[2017-02-01].http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/default.htm.
[2] FDA. CFR-Code of Federal Regulations Title 21 Part 50 Protection of Human Subjects[EB/OL].(2016-04-01)[2017-04-19].https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50&showFR=1.
[3] FDA.CFR-Code of Federal Regulations Title 21 Part 56 Institutional Review Boards[EB/OL].(2016-04-01)[2017-04-19]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=56&showFR=1.
[4] FDA. CFR-Code of Federal Regulations Title 21 Part 312 Investigational New Drug Application[EB/OL].(2016-04-01)[2017-04-19].https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312.
[5] FDA. CPG Sec. 120.100 Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities[EB/OL].(2015-03-20)[2017-02-01].http://www.fda.gov/ICECI/ComplianceManuals/Compli-ancePolicyGuidanceManual/ucm073837.htm.
[6] GAO. Oversight of Clinical Investigators. Action Needed to Improve Timeliness and Enhance Scope of FDA's Debarment and Disqualification Processes for Medical Product Investigators[EB/OL].(2009-09-20)[2017-02-01].http://www.gao.gov/new.items/d09807.pdf.
[7] FDA. Points to Consider for Internal Reviews and Corrective Action Operating Plans June FDA[EB/OL].(2016-04-26)[2017-02-01].https://www.fda.gov/ICECI/EnforcementActions/Applica-tionIntegrityPolicy/ucm134744.htm.
[8] FDA.Clinical Investigators - Disqualification Proceedings[EB/OL]. (2016-12-05)[2017-02-01].http://www.fda.gov/ICECI/Enforce-mentActions/ucm321308.htm#database
[9] FDA.Clinical Investigators-Disqualification Proceedings[EB/OL]. (2017-01-30)[2017-02-01].http://www.accessdata.fda.gov/scripts/SDA/sdNavigation.cfm?sd=clinicalinvestigatorsdisqualificationp-roceedings&previewMode=true&displayAll=true.
[10] FDA. 21 CFR 56 Subpart E[EB/OL].(2016-04-01)[2017-02-01]. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=56&showFR=1&subpartNode=21:1.0.1.1.22.5.
[11] FDA.Institutional Review Boards-Restrictions Imposed Letters and Disqualification Proceedings[EB/OL].(2016-05-31)[2017-02-01].http://www.fda.gov/scienceresearch/specialtopics/runningclinicaltrials/complianceenforcement/ucm369514.htm.
[12] Federal Register. Wesley A. McQuerry: Debarment Order[EB/OL]. (2017-02-27)[2017-02-27].https://www.federalregister.gov/documents/2016/03/18/2016-06104/wesley-a-mcquerry-debarment-order.
[13] 杨帆,陶田甜,邵蓉,等. 药物临床试验中申办者与其他主体的法律关系研究[J]. 中国新药杂志,2016,25(12):1396-1399.
[14] 梁虹.中国临床试验数据质量问题的深层原因及对策分析[J]. 转化医学杂志,2016,5(5):295-297.
[15] 薛薇,董凡,李可欣. 我国新药临床试验的风险管理模式探讨[J]. 中国药物警戒,2014, 11 (8):488-491.
[16] 中华人民共和国最高人民法院.最高法审委会全体会议审议并原则通过《最高人民法院、最高人民检察院关于办理药品、医疗器械注册申请数据造假刑事案件适用法律若干问题的解释》[EB/OL].(2017-04-10)[2017-04-19].http://www.court.gov.cn/zixun-xiangqing-39752.html.
[17] 国家食品药品监督管理总局食品药品审核查验中心.从源头保障药品安全性和有效性 [EB/OL].(2015-12-31)[2017-06-13].http://www.cfdi.org.cn/resource/news/7179.html.